FA
VRTX icon

Fagan Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Fagan Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Sell
26,553
-13
-0% -$6.06K 1.65% 17
2025
Q4 		$12M Buy
26,566
+260
+1% +$112K 1.61% 18
2025
Q3 		$10.3M Buy
26,306
+111
+0.4% +$46.4K 1.42% 21
2025
Q2 		$11.7M Sell
26,195
-90
-0.3% -$41.5K 1.8% 15
2025
Q1 		$12.7M Sell
26,285
-233
-0.9% -$109K 2.13% 13
2024
Q4 		$10.7M Buy
26,518
+93
+0.4% +$43.1K 1.7% 14
2024
Q3 		$12.3M Sell
26,425
-70
-0.3% -$33.6K 2.06% 10
2024
Q2 		$12.4M Buy
26,495
+557
+2% +$242K 2.17% 9
2024
Q1 		$10.8M Buy
25,938
+496
+2% +$210K 2.03% 12
2023
Q4 		$10.4M Buy
25,442
+355
+1% +$131K 2.25% 10
2023
Q3 		$8.72M Buy
25,087
+510
+2% +$178K 2.11% 13
2023
Q2 		$8.65M Buy
24,577
+433
+2% +$146K 2.1% 14
2023
Q1 		$7.61M Sell
24,144
-97
-0.4% -$29.1K 1.89% 16
2022
Q4 		$7M Buy
24,241
+250
+1% +$76.2K 1.87% 15
2022
Q3 		$6.95M Buy
23,991
+270
+1% +$77.7K 1.94% 11
2022
Q2 		$6.68M Sell
23,721
-2,178
-8% -$583K 1.79% 18
2022
Q1 		$6.76M Buy
25,899
+2,480
+11% +$589K 1.39% 23
2021
Q4 		$5.14M Buy
23,419
+3,012
+15% +$586K 0.98% 27
2021
Q3 		$3.7M Sell
20,407
-1,035
-5% -$202K 0.8% 38
2021
Q2 		$4.32M Buy
21,442
+3,157
+17% +$660K 0.92% 33
2021
Q1 		$3.93M Buy
18,285
+14,570
+392% +$3.2M 0.92% 33
2020
Q4 		$878K Buy
+3,715
New +$852K 0.22% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fagan Associates's VRTX Position: Q1 2026 in Review

Fagan Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 0.05% in Q1 2026, selling an estimated $6.06K and leaving 26,553 shares worth $11.9M. The position accounts for 1.65% of the portfolio, ranked #17.

Fagan Associates first reported a position in VRTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $12.7M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fagan Associates held 26,553 shares of Vertex Pharmaceuticals worth $11.9M as of Q1 2026.
  • Fagan Associates sold 13 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.06K.
  • Vertex Pharmaceuticals made up 1.65% of Fagan Associates's portfolio in Q1 2026, its #17 holding.
  • Fagan Associates first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Fagan Associates's Vertex Pharmaceuticals position peaked at $12.7M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fagan Associates's 13F filing for Q1 2026, filed 4 May 2026.